Crenessity (Crinecerfont) for CAH

Overview
Crenessity is approved by the U.S. Food and Drug Administration (FDA) as an adjunctive (add-on) treatment to glucocorticoid replacement for controlling androgen levels in adults and children aged 4 years and older with classic congenital adrenal hyperplasia (CAH). People with CAH must continue glucocorticoid therapy to manage adrenal insufficiency while taking Crenessity. Crenessity is also known by its drug name, crinecerfont.

Crenessity is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist. It works by blocking CRF1 receptors, which may help regulate the overproduction of adrenal androgens that occurs in people with CAH.

How do I take it?
Prescribing information states that Crenessity is taken orally, twice daily with meals, once in the morning and once in the evening. Adults typically take a fixed dose, while children aged 4 years and older receive a weight-based dose. Crenessity is available in capsule form and as an oral solution. This medication should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Crenessity include fatigue, headache, dizziness, arthralgia (joint pain), back pain, decreased appetite, and myalgia (muscle pain) in adults. In children, common side effects include headache, abdominal pain, fatigue, nasal congestion, and epistaxis (nosebleeds).

Rare but serious side effects may include hypersensitivity reactions such as throat tightness, angioedema (swelling beneath the skin), and widespread rash. There is also a risk of acute adrenal insufficiency or adrenal crisis if glucocorticoid therapy is not properly maintained. Glucocorticoid doses should not be reduced below replacement levels, and stress doses may be needed during illness, trauma, or surgery.

For more information about this treatment, visit:

Label: Crenessity — Crinecerfont Capsule; Crenessity — Crinecerfont Solution — DailyMed